Microbot Medical Inc. (MBOT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the sys ...

The addition of the head of Sales Operations & Analytics aims to strengthen sales infrastructure and launch executionHINGHAM, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY Endovascular Robotic System, today announced the continued expansion of its commercial team in preparation for the anticipated U.S. launch of the LIBERTY System, which is projected during the third quarter of 2025. The Company remains actively engaged with the U.S. Food ...

HINGHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY Endovascular Robotic System, announced that it has been selected for inclusion in the preliminary list of additions to the Russell Microcap Index, as published by FTSE Russell on Friday, May 23, 2025. The newly reconstituted indexes are expected to take effect after U.S. market close on Friday, June 27, 2025, and be part of the 2025 Russell indexes reconstitution when the U.S. market o ...

For the transition period from ____ to _____ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission file number: 000-19871 MICROBOT MEDICAL INC. (Name of Registrant in Its Charter) Delaware 94-3078125 State or Other Jurisdiction of In ...

Successful robotic navigation was achieved in every case and met the primary endpoint of the study LIBERTY® showed a 92% reduction in radiation exposure with no adverse events reported HINGHAM, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, presented for the first time the data from its ACCESS-PVI pivotal trial at the Society of Interventional Radiology (SIR) annual meeting. The study was performed at three lea ...

Core Insights - Microbot Medical Inc. is reaffirming its expectation for the FDA's decision regarding the 510(k) clearance of its LIBERTY Endovascular Robotic System during the current second quarter [1][2] - The ACCESS-PVI trial data will be presented for the first time at a podium presentation on April 2, 2025, by Dr. Francois Cornelis from Memorial Sloan Kettering Cancer Center [1][2] Company Overview - Microbot Medical Inc. is a pre-commercial stage medical technology company focused on improving patient care globally [3] - The company has developed the world's first single-use, fully disposable endovascular robotic system, aiming to overcome traditional barriers to advanced robotic systems [3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the fiscal year ended December 31, 2024 Washington, D.C. 20549 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Form 10-K For the transition period from ____ to _____ (Mark One) Commission file number: 000-19871 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorpor ...

Core Insights - Microbot Medical Inc. has appointed Paul Mullen as Vice President of Sales, marking the company's first commercial hire as it prepares for FDA clearance anticipated in Q2 2025 [1][3] Company Overview - Microbot Medical Inc. is a pre-commercial stage medical technology company focused on developing the LIBERTY Endovascular Robotic System, which aims to redefine endovascular robotics and improve patient care globally [4] Appointment Details - Paul Mullen brings extensive experience in the endovascular medical device market, having previously served as Director of Sales at Inari Medical, which was acquired by Stryker Corporation for $4.94 billion [2] - Mullen's responsibilities will include building the sales strategy and infrastructure for a successful product launch following FDA clearance [1][3] Market Context - The endovascular space is critical for treating conditions such as deep vein thrombosis and pulmonary embolisms, with Mullen having successfully launched multiple innovative devices in this area [2] - The company aims to eliminate barriers to access for advanced robotic technologies in the endovascular field, potentially benefiting millions of patients [4]

Research Collaboration demonstrates the feasibility of using the LIBERTY® Endovascular Robotic System between separate and remote facilities in a coronary simulation modelBRAINTREE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today announced its collaboration with Corewell Health™ has reached another meaningful milestone. Under a collaboration agreement, Microbot Medical® and Corewell Health™ are working tog ...

BRAINTREE, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 6,103,289 shares of the Company’s common stock at a purchase price of $2.13 per share of common stock. In addition, in a concurrent private placement, the Company issued unregistered short-term series I preferred investment options. The short-term series I preferred inve ...